EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> ASIT Biotech added to its financing round. The biotech will use the money to move its grass pollen rhinitis treatment into a second phase 3 trial later this year. Release

> Prokarium raised $10 million (€8 million) to support clinical development of vaccines against chlamydia, Clostridium difficile and enteric fever. The British biotech is also expanding its R&D team ahead of a push into immuno-oncology. Statement 

> Bavarian Nordic and AstraZeneca agreed to trial CV301 with Imfinzi. The phase 1/2 trial will assess Bavarian’s cancer vaccine and AstraZeneca’s PD-L1 inhibitor in patients with metastatic colorectal or pancreatic cancers. Release


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Valneva and Emergent Biosolutions moved their Zika virus vaccine into phase 1. Data from the trial will dictate whether Emergent exercises its option on the vaccine. Statement

> OSE Immunotherapeutics got the green light to resume enrollment in its Tedopi phase 3. The biotech halted enrollment in the trial last year “due to an emerging benefit/risk balance of the experimental treatment.” Release

> The Brexit Health Alliance set out how negotiators can mitigate the effect of the U.K.’s departure from the European Union on medical research. Report (PDF)

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.